Profile | GDS2987 / GI_4502644-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 1.5 | 6 |
GSM215244 | HMVEC_vehicle_rep2 | 3.7 | 10 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 0.9 | 2 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 17.4 | 34 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 16.6 | 33 |
GSM215296 | HMVEC_SLx2119_rep3 | 36.8 | 52 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 35.9 | 50 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 17.3 | 27 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 7.4 | 13 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 27.3 | 43 |
GSM215328 | PASMC_SLx2119_rep2 | 8.4 | 16 |
GSM215329 | PASMC_SLx2119_rep3 | 9.1 | 18 |
GSM215330 | Fibroblasts_vehicle_rep1 | 18.7 | 40 |
GSM215331 | Fibroblasts_vehicle_rep2 | 0.5 | 1 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 5.8 | 17 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 7.7 | 25 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 |